Bimekizumab Long-Term Efficacy in Patients With Moderate to Severe Plaque Psoriasis After Switching From Adalimumab, Ustekinumab, or Secukinumab: Results from Up to 4 Years of Total Treatment from BE BRIGHT and BE RADIANT. J of Skin 2024, 8 (6), s433. https://doi.org/10.25251/skin.8.supp.433.